<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36839394</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2072-6643</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>19</Day></PubDate></JournalIssue><Title>Nutrients</Title><ISOAbbreviation>Nutrients</ISOAbbreviation></Journal><ArticleTitle>Nutritional Approaches to Modulate Cardiovascular Disease Risk in Systemic Lupus Erythematosus: A Literature Review.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1036</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/nu15041036</ELocationID><Abstract><AbstractText>Systemic lupus erythematosus (SLE) is a chronic pathology characterized by a bimodal mortality pattern attributed to clinical disease activity and cardiovascular disease (CVD). A complex interaction between traditional CVD risk factors such as obesity, dyslipidemia, smoking, insulin resistance, metabolic syndrome, and hypertension, as well as the presence of non-traditional CVD risk factors such as hyperhomocysteinemia, pro-inflammatory cytokines, and C-reactive protein levels, has been suggested as a cause of the high prevalence of CVD in SLE patients. On the other hand, environmental factors, such as nutritional status, could influence the disease's prognosis; several nutrients have immunomodulators, antioxidants, and anti-cardiometabolic risk properties which could reduce SLE severity and organ damage by decreasing the development of traditional and non-traditional CVD risk factors. Therefore, this critical literature review discusses the therapeutic potential of nutritional approaches that could modulate the development of the main comorbidities related to CVD risk in SLE patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pesqueda-Cendejas</LastName><ForeName>Karen</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-6849-5965</Identifier><AffiliationInfo><Affiliation>Red de Inmunonutrici&#xf3;n y Gen&#xf3;mica Nutricional en las Enfermedades Autoinmunes, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto de Neurociencias Traslacionales, Departamento de Neurociencias, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Programa de Doctorado en Ciencias de la Nutrici&#xf3;n Traslacional, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rivera-Escoto</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9069-7478</Identifier><AffiliationInfo><Affiliation>Red de Inmunonutrici&#xf3;n y Gen&#xf3;mica Nutricional en las Enfermedades Autoinmunes, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto de Neurociencias Traslacionales, Departamento de Neurociencias, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Programa de Doctorado en Ciencias Biom&#xe9;dicas Orientaci&#xf3;n Inmunolog&#xed;a, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meza-Meza</LastName><ForeName>M&#xf3;nica R</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0000-0003-4991-4965</Identifier><AffiliationInfo><Affiliation>Red de Inmunonutrici&#xf3;n y Gen&#xf3;mica Nutricional en las Enfermedades Autoinmunes, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto de Neurociencias Traslacionales, Departamento de Neurociencias, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Programa de Doctorado en Ciencias Biom&#xe9;dicas Orientaci&#xf3;n Inmunolog&#xed;a, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campos-L&#xf3;pez</LastName><ForeName>Bertha</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-1667-8794</Identifier><AffiliationInfo><Affiliation>Red de Inmunonutrici&#xf3;n y Gen&#xf3;mica Nutricional en las Enfermedades Autoinmunes, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto de Neurociencias Traslacionales, Departamento de Neurociencias, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Programa de Doctorado en Ciencias en Biolog&#xed;a Molecular en Medicina, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parra-Rojas</LastName><ForeName>Isela</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-9213-8263</Identifier><AffiliationInfo><Affiliation>Red de Inmunonutrici&#xf3;n y Gen&#xf3;mica Nutricional en las Enfermedades Autoinmunes, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratorio de Investigaci&#xf3;n en Obesidad y Diabetes, Facultad de Ciencias Qu&#xed;mico-Biol&#xf3;gicas, Universidad Aut&#xf3;noma de Guerrero, Chilpancingo de los Bravo 39087, Guerrero, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montoya-Buelna</LastName><ForeName>Margarita</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9309-1957</Identifier><AffiliationInfo><Affiliation>Red de Inmunonutrici&#xf3;n y Gen&#xf3;mica Nutricional en las Enfermedades Autoinmunes, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratorio de Inmunolog&#xed;a, Departamento de Fisiolog&#xed;a, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De la Cruz-Mosso</LastName><ForeName>Ulises</ForeName><Initials>U</Initials><Identifier Source="ORCID">0000-0003-4579-2294</Identifier><AffiliationInfo><Affiliation>Red de Inmunonutrici&#xf3;n y Gen&#xf3;mica Nutricional en las Enfermedades Autoinmunes, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto de Neurociencias Traslacionales, Departamento de Neurociencias, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Programa de Doctorado en Ciencias de la Nutrici&#xf3;n Traslacional, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Programa de Doctorado en Ciencias Biom&#xe9;dicas Orientaci&#xf3;n Inmunolog&#xed;a, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Nutrients</MedlineTA><NlmUniqueID>101521595</NlmUniqueID><ISSNLinking>2072-6643</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="Y">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="Y">Hypertension</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024821" MajorTopicYN="Y">Metabolic Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">C-reactive protein</Keyword><Keyword MajorTopicYN="N">cardiovascular disease risk</Keyword><Keyword MajorTopicYN="N">dyslipidemia</Keyword><Keyword MajorTopicYN="N">hyperhomocysteinemia</Keyword><Keyword MajorTopicYN="N">hypertension</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest. Figures were created with BioRender software, &#xa9;biorender.com.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>2</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>25</Day><Hour>4</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36839394</ArticleId><ArticleId IdType="pmc">PMC9958972</ArticleId><ArticleId IdType="doi">10.3390/nu15041036</ArticleId><ArticleId IdType="pii">nu15041036</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ye Y., Wu T., Zhang T., Han J., Habazi D., Saxena R., Mohan C. Elevated oxidized lipids, anti-lipid autoantibodies and oxidized lipid immune complexes in active SLE. Clin. Immunol. 2019;205:43&#x2013;48. doi: 10.1016/j.clim.2019.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2019.05.004</ArticleId><ArticleId IdType="pubmed">31075396</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinicato N.A. Risk Factors in Cardiovascular Disease in Systemic Lupus Erythematosus. Curr. Cardiol. Rev. 2013;9:15&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3584302</ArticleId><ArticleId IdType="pubmed">23463953</ArticleId></ArticleIdList></Reference><Reference><Citation>Wigren M., Nilsson J., Kaplan M.J. Pathogenic immunity in systemic lupus erythematosus and atherosclerosis: Common mechanisms and possible targets for intervention. J. Intern. Med. 2015;278:494&#x2013;506. doi: 10.1111/joim.12357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.12357</ArticleId><ArticleId IdType="pmc">PMC4550575</ArticleId><ArticleId IdType="pubmed">25720452</ArticleId></ArticleIdList></Reference><Reference><Citation>Croca S., Rahman A. Atherosclerosis in systemic lupus erythematosus. Best Pract Res. Clin. Rheumatol. 2017;31:364&#x2013;372. doi: 10.1016/j.berh.2017.09.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.berh.2017.09.012</ArticleId><ArticleId IdType="pubmed">29224678</ArticleId></ArticleIdList></Reference><Reference><Citation>Meza-Meza M.R., Vizmanos-Lamotte B., Mu&#xf1;oz-Valle J.F., Parra-Rojas I., Garaulet M., Campos-L&#xf3;pez B., Montoya-Buelna M., Cerpa-Cruz S., Mart&#xed;nez-L&#xf3;pez E., Oregon-Romero E., et al. Relationship of Excess Weight with Clinical Activity and Dietary Intake Deficiencies in Systemic Lupus Erythematosus Patients. Nutrients. 2019;11:2683. doi: 10.3390/nu11112683.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu11112683</ArticleId><ArticleId IdType="pmc">PMC6893805</ArticleId><ArticleId IdType="pubmed">31698711</ArticleId></ArticleIdList></Reference><Reference><Citation>Hak A.E., Karlson E.W., Feskanich D., Stampfer M.J., Costenbader K.H. Systemic lupus erythematosus and the risk of cardiovascular disease: Results from the nurses&#x2019; health study. Arthritis Rheum. 2009;61:1396&#x2013;1402. doi: 10.1002/art.24537.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.24537</ArticleId><ArticleId IdType="pmc">PMC2909444</ArticleId><ArticleId IdType="pubmed">19790130</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzi S., Meilahn E.N., Rairie J.E., Conte C.G., Medsger T.A., Jansen-McWilliams L., D&#x2019;Agostino R.B., Kuller L.H. Age-specific Incidence Rates of Myocardial Infarction and Angina in Women with Systemic Lupus Erythematosus: Comparison with the Framingham Study. Am. J. Epidemiol. 1997;145:408&#x2013;415. doi: 10.1093/oxfordjournals.aje.a009122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfordjournals.aje.a009122</ArticleId><ArticleId IdType="pubmed">9048514</ArticleId></ArticleIdList></Reference><Reference><Citation>Karp I., Abrahamowicz M., Fortin P.R., Pilote L., Neville C., Pineau C.A. Esdaile JM. Recent corticosteroid use and recent disease activity: Independent determinants of coronary heart disease risk factors in systemic lupus erythematosus? Arthritis Rheum. 2008;59:169&#x2013;175. doi: 10.1002/art.23352.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.23352</ArticleId><ArticleId IdType="pubmed">18240259</ArticleId></ArticleIdList></Reference><Reference><Citation>Szab&#xf3; M.Z., Szodoray P., Kiss E. Dyslipidemia in systemic lupus erythematosus. Immunol. Res. 2017;65:543&#x2013;550. doi: 10.1007/s12026-016-8892-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12026-016-8892-9</ArticleId><ArticleId IdType="pubmed">28168401</ArticleId></ArticleIdList></Reference><Reference><Citation>Campos-L&#xf3;pez B., Meza-Meza M.R., Parra-Rojas I., Ruiz-Ballesteros A.I., Vizmanos-Lamotte B., Mu&#xf1;oz-Valle J.F., Montoya-Buelna M., Cerpa-Cruz S., Bernal-Hern&#xe1;ndez L.E., De la Cruz-Mosso U. Association of cardiometabolic risk status with clinical activity and damage in systemic lupus erythematosus patients: A cross-sectional study. Clin. Immunol. 2021;222:108637. doi: 10.1016/j.clim.2020.108637.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2020.108637</ArticleId><ArticleId IdType="pubmed">33232825</ArticleId></ArticleIdList></Reference><Reference><Citation>de Miranda Moura dos Santos F., Borges M.C., Telles R.W., Correia M.I.T.D., Lanna C.C.D. Excess weight and associated risk factors in patients with systemic lupus erythematosus. Rheumatol. Int. 2013;33:681&#x2013;688. doi: 10.1007/s00296-012-2402-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-012-2402-8</ArticleId><ArticleId IdType="pubmed">22527136</ArticleId></ArticleIdList></Reference><Reference><Citation>La Cava A. The Influence of Diet and Obesity on Gene Expression in SLE. Genes. 2019;10:405. doi: 10.3390/genes10050405.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes10050405</ArticleId><ArticleId IdType="pmc">PMC6562976</ArticleId><ArticleId IdType="pubmed">31137916</ArticleId></ArticleIdList></Reference><Reference><Citation>Svenungsson E., Gunnarsson I., Fei G.Z., Lundberg I.E., Klareskog L., Frosteg&#xe5;rd J. Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor &#x3b1;/tumor necrosis factor receptor system in systemic lupus erythematosus: Blood Lipids and TNF&#x3b1; Activity in SLE. Arthritis Rheum. 2003;48:2533&#x2013;2540.</Citation><ArticleIdList><ArticleId IdType="pubmed">13130473</ArticleId></ArticleIdList></Reference><Reference><Citation>Oeser A., Chung C.P., Asanuma Y., Avalos I., Stein C.M. Obesity is an independent contributor to functional capacity and inflammation in systemic lupus erythematosus. Arthritis Rheum. 2005;52:3651&#x2013;3659. doi: 10.1002/art.21400.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.21400</ArticleId><ArticleId IdType="pubmed">16258902</ArticleId></ArticleIdList></Reference><Reference><Citation>Klack K., Bonfa E., Neto E.F.B. Diet and nutritional aspects in systemic lupus erythematosus. Rev. Bras. Reumatol. 2012;52:384&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pubmed">22641593</ArticleId></ArticleIdList></Reference><Reference><Citation>Muthukumar A., Zaman K., Lawrence R., Barnes J.L., Fernandes G. Food Restriction and Fish Oil Suppress Atherogenic Risk Factors in Lupus-Prone (NZB &#xd7; NZW) F1 Mice. J. Clin. Immunol. 2002;23:23&#x2013;33. doi: 10.1023/A:1021996130672.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1021996130672</ArticleId><ArticleId IdType="pubmed">12645857</ArticleId></ArticleIdList></Reference><Reference><Citation>Borges M.C., dos Santos F.D.M.M., Telles R.W., Lanna C.C.D., Correia M.I.T. Nutritional status and food intake in patients with systemic lupus erythematosus. Nutrition. 2012;28:1098&#x2013;1103. doi: 10.1016/j.nut.2012.01.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nut.2012.01.015</ArticleId><ArticleId IdType="pubmed">22898268</ArticleId></ArticleIdList></Reference><Reference><Citation>Aparicio-Soto M., S&#xe1;nchez-Hidalgo M., Alarc&#xf3;n-de-la-Lastra C. An update on diet and nutritional factors in systemic lupus erythematosus management. Nutr. Res. Rev. 2017;30:118&#x2013;137. doi: 10.1017/S0954422417000026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0954422417000026</ArticleId><ArticleId IdType="pubmed">28294088</ArticleId></ArticleIdList></Reference><Reference><Citation>Versini M., Jeandel P., Rosenthal E., Shoenfeld Y. Obesity in autoimmune diseases: Not a passive bystander. Autoimmun. Rev. 2014;13:981&#x2013;1000. doi: 10.1016/j.autrev.2014.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2014.07.001</ArticleId><ArticleId IdType="pubmed">25092612</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagar D., Gaddipati R., Ongstad E.L., Bhagroo N., An L.L., Wang J., Belkhodja M., Rahman S., Manna Z., Davis M.A. LOX-1: A potential driver of cardiovascular risk in SLE patients. PLoS ONE. 2020;15:1&#x2013;23. doi: 10.1371/journal.pone.0229184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0229184</ArticleId><ArticleId IdType="pmc">PMC7077835</ArticleId><ArticleId IdType="pubmed">32182251</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeller C., Appenzeller S. Cardiovascular Disease in Systemic Lupus Erythematosus: The Role of Traditional and Lupus Related Risk Factors. Cur. Cardiol. Rev. 2008;4:116&#x2013;122. doi: 10.2174/157340308784245775.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/157340308784245775</ArticleId><ArticleId IdType="pmc">PMC2779351</ArticleId><ArticleId IdType="pubmed">19936286</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao N., Kong M., Li X., Wei D., Zhu X., Hong Z., Ni M., Wang Y., Dong A. Systemic Lupus Erythematosus and Cardiovascu-lar Disease: A Mendelian Randomization Study. Front. Immunol. 2022;13:908831. doi: 10.3389/fimmu.2022.908831.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.908831</ArticleId><ArticleId IdType="pmc">PMC9207262</ArticleId><ArticleId IdType="pubmed">35734181</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahlenberg J.M., Kaplan M.J. The interplay of inflammation and cardiovascular disease in systemic lupus erythematosus. Arthritis Res. Ther. 2011;13:203. doi: 10.1186/ar3264.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar3264</ArticleId><ArticleId IdType="pmc">PMC3157642</ArticleId><ArticleId IdType="pubmed">21371346</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercurio V., Lobasso A., Barbieri L., Parrella P., Ciervo D., Liccardo B., Bonaduce D., Tocchetti C.G., De Paulis A., Rossi F.W. Inflammatory, serological and vascular determinants of cardiovascular disease in systemic lupus erythematosus patients. Int. J. Mol. Sci. 2019;20:2154. doi: 10.3390/ijms20092154.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20092154</ArticleId><ArticleId IdType="pmc">PMC6540240</ArticleId><ArticleId IdType="pubmed">31052336</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizk A., Gheita T.A., Nassef S., Abdallah A. The impact of obesity in systemic lupus erythematosus on disease parameters, quality of life, functional capacity and the risk of atherosclerosis: Obesity in SLE. Int. J. Rheum. Dis. 2012;15:261&#x2013;267. doi: 10.1111/j.1756-185X.2011.01698.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1756-185X.2011.01698.x</ArticleId><ArticleId IdType="pubmed">22212605</ArticleId></ArticleIdList></Reference><Reference><Citation>Salom&#xe3;o R.G., de Carvalho L.M., Izumi C., Czernisz &#xc9;.S., Rosa J.C., Antonini S.R.R., Bueno A.C., Almada M.O.R.D.V., Coelho-Landell C.D.A., Jord&#xe3;o A.A., et al. Homocysteine, folate, hs-C-reactive protein, tumor necrosis factor alpha and inflammatory proteins: Are these biomarkers related to nutritional status and cardiovascular risk in childhood-onset systemic lupus erythematosus? Pediatr. Rheumatol. Online J. 2018;16:4. doi: 10.1186/s12969-017-0220-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12969-017-0220-y</ArticleId><ArticleId IdType="pmc">PMC5761099</ArticleId><ArticleId IdType="pubmed">29316941</ArticleId></ArticleIdList></Reference><Reference><Citation>Urowitz M.B., Gladman D., Iba&#xf1;ez D., Fortin P., Sanchez-Guerrero J., Bae S., Clarke A., Bernatsky S., Gordon C., Hanly J. Accumulation of coronary artery disease risk factors over three years: Data from an international inception cohort. Arthritis Rheum. 2008;59:176&#x2013;180. doi: 10.1002/art.23353.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.23353</ArticleId><ArticleId IdType="pubmed">18240193</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu H., Chung Y. Dyslipidemia promotes germinal center reactions via IL-27. BMB Rep. 2018;51:371&#x2013;372. doi: 10.5483/BMBRep.2018.51.8.171.</Citation><ArticleIdList><ArticleId IdType="doi">10.5483/BMBRep.2018.51.8.171</ArticleId><ArticleId IdType="pmc">PMC6130833</ArticleId><ArticleId IdType="pubmed">30037367</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel R., Dwivedi M., Mansuri M.S. Association of Neuropeptide-Y (NPY) and Phenotype Correlation and Plasma Lipids with Type-II Diabetes. PLoS ONE. 2016;11:e0164437. doi: 10.1371/journal.pone.0164437.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0164437</ArticleId><ArticleId IdType="pmc">PMC5066977</ArticleId><ArticleId IdType="pubmed">27749914</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung C.P., Avalos I., Oeser A., Gebretsadik T., Shintani A., Raggi P., Stein C.M. High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: Association with disease characteristics and cardiovascular risk factors. Ann. Rheum. Dis. 2007;66:208&#x2013;214. doi: 10.1136/ard.2006.054973.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2006.054973</ArticleId><ArticleId IdType="pmc">PMC1798504</ArticleId><ArticleId IdType="pubmed">16901956</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannelou M., Mavragani C.P. Cardiovascular disease in systemic lupus erythematosus: A comprehensive update. J. Autoimmun. 2017;82:1&#x2013;12. doi: 10.1016/j.jaut.2017.05.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2017.05.008</ArticleId><ArticleId IdType="pubmed">28606749</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman B.T., Shaw K.M., Kuklina E.V., Callaghan W.M., Seely E.W., Hern&#xe1;ndez-D&#xed;az S. Hypertension in Women of Reproductive Age in the United States: NHANES 1999-2008. PLoS ONE. 2012;7:e36171. doi: 10.1371/journal.pone.0036171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0036171</ArticleId><ArticleId IdType="pmc">PMC3340351</ArticleId><ArticleId IdType="pubmed">22558371</ArticleId></ArticleIdList></Reference><Reference><Citation>Munguia-Realpozo P., Mendoza-Pinto C., Sierra Benito C., Escarcega R.O., Garcia-Carrasco M., Mendez Martinez S., Etchegaray Morales I., Galvez Romero J.L., Ruiz-Arguelles A., Cervera R. Systemic lupus erythematosus and hypertension. Autoimmun. Rev. 2019;18:102371. doi: 10.1016/j.autrev.2019.102371.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2019.102371</ArticleId><ArticleId IdType="pubmed">31415907</ArticleId></ArticleIdList></Reference><Reference><Citation>Cio&#x142;kiewicz M., Kuryliszyn-Moskal A., Klimiuk P.A. Analysis of correlations between selected endothelial cell activation markers, disease activity, and nailfold capillaroscopy microvascular changes in systemic lupus erythematosus patients. Clin. Rheumatol. 2010;29:175&#x2013;180. doi: 10.1007/s10067-009-1308-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-009-1308-7</ArticleId><ArticleId IdType="pubmed">19907914</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell J.A., Hamer M., David Batty G., Singh-Manoux A., Sabia S., Kivimaki M. Combined effect of physical activity and leisure time sitting on long-term risk of incident obesity and metabolic risk factor clustering. Diabetologia. 2014;57:2048&#x2013;2056. doi: 10.1007/s00125-014-3323-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-014-3323-8</ArticleId><ArticleId IdType="pmc">PMC4153972</ArticleId><ArticleId IdType="pubmed">25078481</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddigan J.I., Ardern C.I., Riddell M.C., Kuk J.L. Relation of physical activity to cardiovascular disease mortality and the influence of cardiometabolic risk factors. Am. J. Cardiol. 2011;108:1426&#x2013;1431. doi: 10.1016/j.amjcard.2011.07.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2011.07.005</ArticleId><ArticleId IdType="pubmed">21855834</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohl H.W., Craig C.L., Lambert E.V., Inoue S., Alkandari J.R., Leetongin G., Kahlmeier S., Andersen L.B., Bauman A.E., Blair S.N. The pandemic of physical inactivity: Global action for public health. Lancet. 2012;380:294&#x2013;305. doi: 10.1016/S0140-6736(12)60898-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(12)60898-8</ArticleId><ArticleId IdType="pubmed">22818941</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Dwyer T., Durcan L., Wilson F. Exercise and physical activity in systemic lupus erythematosus: A systematic review with meta-analyses. Semin. Arthritis Rheum. 2017;47:204&#x2013;215. doi: 10.1016/j.semarthrit.2017.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2017.04.003</ArticleId><ArticleId IdType="pubmed">28477898</ArticleId></ArticleIdList></Reference><Reference><Citation>Margiotta D.P.E., Basta F., Dolcini G., Batani V., Vullo M.L., Vernuccio A., Navarini L., Afeltra A. Physical activity and sedentary behavior in patients with Systemic Lupus Erythematosus. PLoS ONE. 2018;13:e0193728. doi: 10.1371/journal.pone.0193728.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0193728</ArticleId><ArticleId IdType="pmc">PMC5837187</ArticleId><ArticleId IdType="pubmed">29505598</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok C.C. Metabolic syndrome and systemic lupus erythematosus: The connection. Expert. Rev. Clin. Immunol. 2019;15:765&#x2013;775. doi: 10.1080/1744666X.2019.1620601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1744666X.2019.1620601</ArticleId><ArticleId IdType="pubmed">31094570</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A., Palfrey H.A., Pathak R., Kadowitz P.J., Gettys T.W., Murthy S.N. The metabolism and significance of homocysteine in nutrition and health. Nut. Metab. 2017;14:78. doi: 10.1186/s12986-017-0233-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12986-017-0233-z</ArticleId><ArticleId IdType="pmc">PMC5741875</ArticleId><ArticleId IdType="pubmed">29299040</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannelou M., Nezos A., Fragkioudaki S., Kasara D., Maselou K., Drakoulis N., Ioakeimidis D., Moutsopoulos H.M., Mavragani C.P. Contribution of MTHFR gene variants in lupus related subclinical atherosclerosis. Clin. Immunol. 2018;193:110&#x2013;117. doi: 10.1016/j.clim.2018.02.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2018.02.014</ArticleId><ArticleId IdType="pubmed">29501539</ArticleId></ArticleIdList></Reference><Reference><Citation>Sam N.B., Zhang Q., Li B.Z., Li X.M., Wang D.G., Pan H.F., Ye D.Q. Serum/plasma homocysteine levels in patients with systemic lupus erythematosus: A systematic review and meta-analysis. Clin. Rheumatol. 2020;39:1725&#x2013;1736. doi: 10.1007/s10067-020-04985-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-020-04985-w</ArticleId><ArticleId IdType="pubmed">32090304</ArticleId></ArticleIdList></Reference><Reference><Citation>Timlin H., Manno R., Douglas H. Hyperhomocysteinemia and Lupus Nephritis. Cureus. 2019;11:e5065. doi: 10.7759/cureus.5065.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.5065</ArticleId><ArticleId IdType="pmc">PMC6721921</ArticleId><ArticleId IdType="pubmed">31516776</ArticleId></ArticleIdList></Reference><Reference><Citation>Kostopoulou M., Nikolopoulos D., Parodis I., Bertsias G. Cardiovascular Disease in Systemic Lupus Erythematosus: Recent data on epidemiology, risk factors and prevention. Curr. Vasc. Pharmacol. 2020;18:549&#x2013;565. doi: 10.2174/1570161118666191227101636.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1570161118666191227101636</ArticleId><ArticleId IdType="pubmed">31880245</ArticleId></ArticleIdList></Reference><Reference><Citation>Schreiber K., Sciascia S., De Groot P.G., Devreese K., Jacobsen S., Ruiz-Irastroza G., Salmon J.E., Shoenfeld Y., Shovman O., Hunt B.J. Antiphospholipid syndrome. Nat. Rev. Dis. Primers. 2018;4:17103. doi: 10.1038/nrdp.2017.103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.103</ArticleId><ArticleId IdType="pubmed">29321641</ArticleId></ArticleIdList></Reference><Reference><Citation>Tektonidou M.G., Laskari K., Panagiotakos D.B., Moutsopoulos H.M. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum. 2009;61:29&#x2013;36. doi: 10.1002/art.24232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.24232</ArticleId><ArticleId IdType="pubmed">19116963</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Xie Y., Zhou H., Xu Y., Liu J., Xie H., Yan J. Involvement of TLR4 in oxidized LDL/&#x3b2;2GPI/Anti-&#x3b2;2GPI-induced transformation of macrophages to foam cells. J. Atheroscler. Thromb. 2014;21:1140&#x2013;1151. doi: 10.5551/jat.24372.</Citation><ArticleIdList><ArticleId IdType="doi">10.5551/jat.24372</ArticleId><ArticleId IdType="pubmed">24998486</ArticleId></ArticleIdList></Reference><Reference><Citation>Rho Y.H., Chung C.P., Oeser A., Solus J., Raggi P., Gebretsadik T., Shintani A., Stein C.M. Novel cardiovascular risk factors in premature coronary atherosclerosis associated with systemic lupus erythematosus. J. Rheumatol. 2008;35:1789&#x2013;1794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2574747</ArticleId><ArticleId IdType="pubmed">18634156</ArticleId></ArticleIdList></Reference><Reference><Citation>Atisha-Fregoso Y., Lima G., Carrillo-Maravilla E., Posadas-S&#xe1;nchez R., P&#xe9;rez-Hern&#xe1;ndez N., Ba&#xf1;os-Pel&#xe1;ez M., Iturralde-Ch&#xe1;vez A., Hern&#xe1;ndez-D&#xed;az N., Jakez-Ocampo J., Rodr&#xed;guez-P&#xe9;rez J.M. C-reactive protein (CRP) polymorphisms and haplotypes are associated with SLE susceptibility and activity but not with serum CRP levels in Mexican population. Clin. Rheumatol. 2018;37:1817&#x2013;1824. doi: 10.1007/s10067-018-4059-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-018-4059-5</ArticleId><ArticleId IdType="pubmed">29556849</ArticleId></ArticleIdList></Reference><Reference><Citation>Momiyama Y., Ohmori R., Fayad Z.A., Kihara T., Tanaka N., Kato R., Taniguchi H., Nagata M., Nakamura H., Ohsuzu F. Associations between plasma C-reactive protein levels and the severities of coronary and aortic atherosclerosis. J. Atheroscler. Thromb. 2010;17:460&#x2013;467. doi: 10.5551/jat.2931.</Citation><ArticleIdList><ArticleId IdType="doi">10.5551/jat.2931</ArticleId><ArticleId IdType="pubmed">20134100</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai M.M., Li C.I., Kardia S.L., Liu C.S., Lin W.Y., Lee Y.D., Chang P.C., Lin C.C., Li T.C. Sex difference in the association of metabolic syndrome with high sensitivity C-reactive protein in a Taiwanese population. BMC Public Health. 2010;10:429. doi: 10.1186/1471-2458-10-429.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2458-10-429</ArticleId><ArticleId IdType="pmc">PMC2920887</ArticleId><ArticleId IdType="pubmed">20663138</ArticleId></ArticleIdList></Reference><Reference><Citation>Wee C.C., Mukamal K.J., Huang A., Davis R.B., McCarthy E.P., Mittleman M.A. Obesity and C-reactive protein levels among white, black, and hispanic US adults. Obesity. 2008;16:875&#x2013;880. doi: 10.1038/oby.2008.7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/oby.2008.7</ArticleId><ArticleId IdType="pmc">PMC2848449</ArticleId><ArticleId IdType="pubmed">18379563</ArticleId></ArticleIdList></Reference><Reference><Citation>Flores-Alfaro E., Fern&#xe1;ndez-Tilapa G., Salazar-Mart&#xed;nez E., Cruz M., Illades-Aguiar B., Parra-Rojas I. Common variants in the CRP gene are associated with serum C-reactive protein levels and body mass index in healthy individuals in Mexico. Genet. Mol. Res. 2012;11:2258&#x2013;2267. doi: 10.4238/2012.May.14.5.</Citation><ArticleIdList><ArticleId IdType="doi">10.4238/2012.May.14.5</ArticleId><ArticleId IdType="pubmed">22614460</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanly J.G., O&#x2019;Keeffe A.G., Su L., Urowitz M.B., Romero-Diaz J., Gordon C., Bae S.C., Bernatsky S., Clarke A.E., Wallace D.J. The frequency and outcome of lupus nephritis: Results from an international inception cohort study. Rheumatology. 2015;55:252&#x2013;262. doi: 10.1093/rheumatology/kev311.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kev311</ArticleId><ArticleId IdType="pmc">PMC4939728</ArticleId><ArticleId IdType="pubmed">26342222</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermansen M.L.F., Lindhardsen J., Torp-Pedersen C., Faurschou M., Jacobsen S. Incidence of systemic lupus erythematosus and lupus nephritis in Denmark: A nationwide cohort study. J. Rheumatol. 2016;43:1335&#x2013;1339. doi: 10.3899/jrheum.151221.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.151221</ArticleId><ArticleId IdType="pubmed">27134247</ArticleId></ArticleIdList></Reference><Reference><Citation>Maningding E., Dall&#x2019;Era M., Trupin L., Murphy L.B., Yazdany J. Racial and Ethnic Differences in the Prevalence and Time to Onset of Manifestations of Systemic Lupus Erythematosus: The California Lupus Surveillance Project. Arthritis Care Res. 2020;72:622&#x2013;629. doi: 10.1002/acr.23887.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.23887</ArticleId><ArticleId IdType="pmc">PMC6872905</ArticleId><ArticleId IdType="pubmed">31115180</ArticleId></ArticleIdList></Reference><Reference><Citation>Wells D.K., Ward M.M. Nephritis and the risk of acute myocardial infarction in patients with systemic lupus erythematosus. Clin. Exp. Rheumatol. 2010;28:223&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2952830</ArticleId><ArticleId IdType="pubmed">20483044</ArticleId></ArticleIdList></Reference><Reference><Citation>Formiga F., Meco J.F., Pinto X., Jacob J., Moga I., Pujol R. Lipid and lipoprotein levels in premenopausal systemic lupus erythematosus patients. Lupus. 2001;10:359&#x2013;363. doi: 10.1191/096120301669070811.</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/096120301669070811</ArticleId><ArticleId IdType="pubmed">11403267</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaabane S., Messedi M., Akrout R., Ben Hamad M., Turki M., Marzouk S., Keskes L., Bahloul Z., Rebai A., Ayedi F., et al. Association of hyperhomocysteinemia with genetic variants in key enzymes of homocysteine metabolism and methotrexate toxicity in rheumatoid arthritis patients. Inflamm. Res. 2018;67:703&#x2013;710. doi: 10.1007/s00011-018-1161-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00011-018-1161-8</ArticleId><ArticleId IdType="pubmed">29796841</ArticleId></ArticleIdList></Reference><Reference><Citation>Oosterom N., de Jonge R., Smith D.E.C., Pieters R., Tissing W.J.E., Fiocco M., van Zelst B.D., van den Heuvel-Eibrink M.M., Heil S.G. Changes in intracellular folate metabolism during high-dose methotrexate and Leucovorin rescue therapy in children with acute lymphoblastic leukemia. Tiziani S, editor. PLoS ONE. 2019;14:e0221591. doi: 10.1371/journal.pone.0221591.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0221591</ArticleId><ArticleId IdType="pmc">PMC6748431</ArticleId><ArticleId IdType="pubmed">31527879</ArticleId></ArticleIdList></Reference><Reference><Citation>Costedoat-Chalumeau N., Dunogu&#xe9; B., Morel N., Le Guern V., Guettrot-Imbert G. Hydroxychloroquine: A multifaceted treatment in lupus. Presse. Med. 2014;43:e167&#x2013;e180. doi: 10.1016/j.lpm.2014.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lpm.2014.03.007</ArticleId><ArticleId IdType="pubmed">24855048</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao C.Y., Shang J., Chen T., Yu D., Jiang Y.M., Liu D., Cheng G.Y., Xiao J., Zhao Z.Z. Impact of antimalarial (AM) on serum lipids in systemic lupus erythematosus (SLE) patients: A systematic review and meta-analysis. Medicine. 2019;98:e15030. doi: 10.1097/MD.0000000000015030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000015030</ArticleId><ArticleId IdType="pmc">PMC6456110</ArticleId><ArticleId IdType="pubmed">30946340</ArticleId></ArticleIdList></Reference><Reference><Citation>Floris A., Piga M., Mangoni A.A., Bortoluzzi A., Erre G.L., Cauli A. Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus. Mediat. Inflamm. 2018;2018:3424136. doi: 10.1155/2018/3424136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/3424136</ArticleId><ArticleId IdType="pmc">PMC5835241</ArticleId><ArticleId IdType="pubmed">29670462</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagler T.A., Neuhofer A., Laggner H., Strobl W., Stangl H. Cholesterol efflux via HDL resecretion occurs when cholesterol transport out of the lysosome is impaired. J. Lipid Res. 2007;48:2141&#x2013;2150. doi: 10.1194/jlr.M700056-JLR200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.M700056-JLR200</ArticleId><ArticleId IdType="pubmed">17620658</ArticleId></ArticleIdList></Reference><Reference><Citation>Ignatescu M.C., Kletzmayr J., F&#xf6;dinger M., Bieglmayer C., H&#xf6;rl W.H., Sunder-Plassmann G. Influence of mycophenolic acid and tacrolimus on homocysteine metabolism. Kidney Int. 2002;61:1894&#x2013;1898. doi: 10.1046/j.1523-1755.2002.00325.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1523-1755.2002.00325.x</ArticleId><ArticleId IdType="pubmed">11967042</ArticleId></ArticleIdList></Reference><Reference><Citation>Segal R., Baumoehl Y., Elkayam O., Levartovsky D., Litinsky I., Paran D., Wigler I., Habot B., Leibovitz A., Sela B.A., et al. anemia, serum vitamin B12, and folic acid in patients with rheumatoid arthritis, psoriatic arthritis, and systemic lupus erythematosus. Rheumatol. Int. 2004;24:14&#x2013;19. doi: 10.1007/s00296-003-0323-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-003-0323-2</ArticleId><ArticleId IdType="pubmed">12720045</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunter P.M., Hegele R.A. Functional foods and dietary supplements for the management of dyslipidaemia. Nat. Rev. En-docrinol. 2017;13:278&#x2013;288. doi: 10.1038/nrendo.2016.210.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrendo.2016.210</ArticleId><ArticleId IdType="pubmed">28133369</ArticleId></ArticleIdList></Reference><Reference><Citation>Babiker R., Elmusharaf K., Keogh M.B., Saeed A.M. Effect of Gum Arabic (Acacia Senegal) supplementation on visceral adiposity index (VAI) and blood pressure in patients with type 2 diabetes mellitus as indicators of cardiovascular disease (CVD): A randomized and placebo-controlled clinical trial. Lipids Health Dis. 2018;17:56. doi: 10.1186/s12944-018-0711-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12944-018-0711-y</ArticleId><ArticleId IdType="pmc">PMC5859434</ArticleId><ArticleId IdType="pubmed">29558953</ArticleId></ArticleIdList></Reference><Reference><Citation>Minami Y., Sasaki T., Arai Y., Kurisu Y., Hisamichi S. Diet and Systemic Lupus Erythematosus: A 4 Year Prospective Study of Japanese Patients. J. Rheumatol. 2003;30:747&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pubmed">12672194</ArticleId></ArticleIdList></Reference><Reference><Citation>Selhub J., Morris M.S., Jacques P.F. In vitamin B 12 deficiency, higher serum folate is associated with increased total homocysteine and methylmalonic acid concentrations. Proc. Natl. Acad. Sci. USA. 2007;104:19995&#x2013;20000. doi: 10.1073/pnas.0709487104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0709487104</ArticleId><ArticleId IdType="pmc">PMC2148411</ArticleId><ArticleId IdType="pubmed">18056804</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandrasekar B., Troyer D.A., Venkatraman J.T., Fernandes G. Dietary Omega-3 Lipids Delay the Onset and Progression of Autoimmune Lupus Nephritis by Inhibiting Transforming Growth Factor mRNA and Protein Expression. J. Autoimmun. 1994;13:381&#x2013;393. doi: 10.1006/jaut.1995.0030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/jaut.1995.0030</ArticleId><ArticleId IdType="pubmed">7575999</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinoshita K., Yoo B.S., Nozaki Y., Sugiyama M., Ikoma S., Ohno M., Funauchi M., Kanamaru A. Retinoic Acid Reduces Autoimmune Renal Injury and Increases Survival in NZB/W F 1 Mice. J. Immunol. 2003;170:5793&#x2013;5798. doi: 10.4049/jimmunol.170.11.5793.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.170.11.5793</ArticleId><ArticleId IdType="pubmed">12759464</ArticleId></ArticleIdList></Reference><Reference><Citation>Weimann J., Weiser H. Effects of Antioxidant Vitamins C, E, and p-Carotene on Immune Functions in MRL/lpr Mice and Rats. Ann. N. Y. Acad. Sci. 1992;669:390&#x2013;392. doi: 10.1111/j.1749-6632.1992.tb17132.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.1992.tb17132.x</ArticleId><ArticleId IdType="pubmed">1444056</ArticleId></ArticleIdList></Reference><Reference><Citation>Strickland F.M., Hewagama A., Wu A., Sawalha A.H., Delaney C., Hoeltzel M.F., Yung R., Johnson K., Mickelson B., Richardson B.C. Diet Influences Expression of Autoimmune-Associated Genes and Disease Severity by Epigenetic Mechanisms in a Transgenic Mouse Model of Lupus: Diet, DNA Methylation, and Lupus. Arthritis Rheum. 2013;65:1872&#x2013;1881. doi: 10.1002/art.37967.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.37967</ArticleId><ArticleId IdType="pmc">PMC3735138</ArticleId><ArticleId IdType="pubmed">23576011</ArticleId></ArticleIdList></Reference><Reference><Citation>Piantoni S., Andreoli L., Scarsi M., Zanola A., Dall&#x2019;Ara F., Pizzorni C., Cutolo M., Air&#xf2; P., Tincani A. Phenotype modifications of T-cells and their shift toward a Th2 response in patients with systemic lupus erythematosus supplemented with different monthly regimens of vitamin D. Lupus. 2015;24:490&#x2013;498. doi: 10.1177/0961203314559090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203314559090</ArticleId><ArticleId IdType="pubmed">25801892</ArticleId></ArticleIdList></Reference><Reference><Citation>Soni C., Sinha I., Fasnacht M.J., Olsen N.J., Rahman Z.S.M., Sinha R. Selenium supplementation suppresses immunological and serological features of lupus in B6. Sle1b mice. Autoimmunity. 2019;52:57&#x2013;68. doi: 10.1080/08916934.2019.1603297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08916934.2019.1603297</ArticleId><ArticleId IdType="pmc">PMC8761364</ArticleId><ArticleId IdType="pubmed">31006265</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown A.C. Lupus erythematosus and nutrition: A review of the literature. J. Ren. Nutr. 2000;10:170&#x2013;183. doi: 10.1053/jren.2000.16323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/jren.2000.16323</ArticleId><ArticleId IdType="pubmed">11070144</ArticleId></ArticleIdList></Reference><Reference><Citation>Perl A., Hanczko R., Lai Z.W., Oaks Z., Kelly R., Borsuk R., Asara J.M., Phillips P.E. Comprehensive metabolome analyses reveal N-acetylcysteine-responsive accumulation of kynurenine in systemic lupus erythematosus: Implications for activation of the mechanistic target of rapamycin. Metabolomics. 2015;11:1157&#x2013;1174. doi: 10.1007/s11306-015-0772-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11306-015-0772-0</ArticleId><ArticleId IdType="pmc">PMC4559110</ArticleId><ArticleId IdType="pubmed">26366134</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai Z.W., Hanczko R., Bonilla E., Caza T.N., Clair B., Bartos A., Miklossy G., Jimah J., Doherty E., Tily H., et al. N -acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: A randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2012;64:2937&#x2013;2946. doi: 10.1002/art.34502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34502</ArticleId><ArticleId IdType="pmc">PMC3411859</ArticleId><ArticleId IdType="pubmed">22549432</ArticleId></ArticleIdList></Reference><Reference><Citation>Procaccini C., De Rosa V., Galgani M., Carbone F., Cassano S., Greco D., Qian K., Auvinen P., Cal&#xec; G., Stallone G., et al. Leptin-Induced mTOR Activation Defines a Specific Molecular and Transcriptional Signature Controlling CD4 + Effector T Cell Responses. J. Immunol. 2012;189:2941&#x2013;2953. doi: 10.4049/jimmunol.1200935.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1200935</ArticleId><ArticleId IdType="pubmed">22904304</ArticleId></ArticleIdList></Reference><Reference><Citation>Leiba A., Amital H., Gershwin M.E., Shoenfeld Y. Diet and lupus. Lupus. 2001;10:246&#x2013;248. doi: 10.1191/096120301674681790.</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/096120301674681790</ArticleId><ArticleId IdType="pubmed">11315362</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahon M., Hahn B.H., Skaggs B.J. Systemic lupus erythematosus and cardiovascular disease: Prediction and potential for therapeutic intervention. Expert Rev. Clin. Immunol. 2011;7:227&#x2013;241. doi: 10.1586/eci.10.98.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/eci.10.98</ArticleId><ArticleId IdType="pmc">PMC3718673</ArticleId><ArticleId IdType="pubmed">21426260</ArticleId></ArticleIdList></Reference><Reference><Citation>Pestka J.J. n-3 Polyunsaturated fatty acids and autoimmune-mediated glomerulonephritis. Prostaglandins Leukot. Essent. Fatty Acids. 2010;82:251&#x2013;258. doi: 10.1016/j.plefa.2010.02.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.plefa.2010.02.013</ArticleId><ArticleId IdType="pmc">PMC2885141</ArticleId><ArticleId IdType="pubmed">20189790</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer B.J., Mann N.J., Lewis J.L., Milligan G.C., Sinclair A.J., Howe P.R.C. Dietary intakes and food sources of omega-6 and omega-3 polyunsaturated fatty acids. Lipids. 2003;38:391&#x2013;398. doi: 10.1007/s11745-003-1074-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11745-003-1074-0</ArticleId><ArticleId IdType="pubmed">12848284</ArticleId></ArticleIdList></Reference><Reference><Citation>Duffy E.M., Meenagh G.K., McMILLAN S.A., Strain J.J., Hannigan B.M., Bell A.L. The Clinical Effect of Dietary Supplementation with Omega-3 Fish Oils and/or Copper in Systemic Lupus Erythematosus. J. Rheumatol. 2004;31:1551&#x2013;1556.</Citation><ArticleIdList><ArticleId IdType="pubmed">15290734</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M. Diet and systemic lupus erythematosus: From mouse and monkey to woman? Lupus. 2001;10:775&#x2013;777. doi: 10.1177/096120330101001102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/096120330101001102</ArticleId><ArticleId IdType="pubmed">11789485</ArticleId></ArticleIdList></Reference><Reference><Citation>Fassett R.G., Gobe G.C., Peake J.M., Coombes J.S. Omega-3 Polyunsaturated Fatty Acids in the Treatment of Kidney Disease. Am. J. Kidney Dis. 2010;56:728&#x2013;742. doi: 10.1053/j.ajkd.2010.03.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2010.03.009</ArticleId><ArticleId IdType="pubmed">20493605</ArticleId></ArticleIdList></Reference><Reference><Citation>Halade G.V., Rahman M.M., Bhattacharya A., Barnes J.L., Chandrasekar B., Fernandes G. Docosahexaenoic Acid-Enriched Fish Oil Attenuates Kidney Disease and Prolongs Median and Maximal Life Span of Autoimmune Lupus-Prone Mice. J. Immunol. 2010;184:5280&#x2013;5286. doi: 10.4049/jimmunol.0903282.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0903282</ArticleId><ArticleId IdType="pmc">PMC2952419</ArticleId><ArticleId IdType="pubmed">20368275</ArticleId></ArticleIdList></Reference><Reference><Citation>Carracedo M., Artiach G., Arnardottir H., B&#xe4;ck M. The resolution of inflammation through omega-3 fatty acids in atherosclerosis, intimal hyperplasia, and vascular calcification. Semin. Immunopathol. 2019;41:757&#x2013;766. doi: 10.1007/s00281-019-00767-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-019-00767-y</ArticleId><ArticleId IdType="pmc">PMC6881483</ArticleId><ArticleId IdType="pubmed">31696250</ArticleId></ArticleIdList></Reference><Reference><Citation>Conte M.S., Desai T.A., Wu B., Schaller M., Werlin E. Pro-resolving lipid mediators in vascular disease. J. Clin. Invest. 2018;128:3727&#x2013;3735. doi: 10.1172/JCI97947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI97947</ArticleId><ArticleId IdType="pmc">PMC6118638</ArticleId><ArticleId IdType="pubmed">30168805</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao X., Ren J., Wei C.H., Ross A.C., Cecere T.E., Jortner B.S., Ahmed S.A., Luo X.M. Paradoxical Effects of All-Trans-Retinoic Acid on Lupus-Like Disease in the MRL/lpr Mouse Model. PLoS ONE. 2015;10:e0118176. doi: 10.1371/journal.pone.0118176.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0118176</ArticleId><ArticleId IdType="pmc">PMC4361690</ArticleId><ArticleId IdType="pubmed">25775135</ArticleId></ArticleIdList></Reference><Reference><Citation>De Lema G.P., Lucio-Caza&#xf1;a F.J., Molina A.N.A., Luckow B., Schmid H., de Wit C., Moreno-Manzano V., Banas B., Mampaso F., Schl&#xf6;ndorff D. Retinoic acid treatment protects MRL/lpr lupus mice from the development of glomerular disease. Kidney Int. 2004;66:1018&#x2013;1028. doi: 10.1111/j.1523-1755.2004.00850.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1523-1755.2004.00850.x</ArticleId><ArticleId IdType="pubmed">15327395</ArticleId></ArticleIdList></Reference><Reference><Citation>Patavino T., Brady D.M. Natural Medicine and Nutritional Therapy as an Alternative Treatment in Systemic Lupus Erythematosus. Altern. Med. Rev. 2001;6:460&#x2013;471.</Citation><ArticleIdList><ArticleId IdType="pubmed">11703166</ArticleId></ArticleIdList></Reference><Reference><Citation>Padayatty S.J., Katz A., Wang Y., Eck P., Kwon O., Lee J.H., Chen S., Corpe C., Dutta A., Dutta S.K., et al. Vitamin C as an Antioxidant: Evaluation of Its Role in Disease Prevention. J. Am. Coll. Nutr. 2003;22:18&#x2013;35. doi: 10.1080/07315724.2003.10719272.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07315724.2003.10719272</ArticleId><ArticleId IdType="pubmed">12569111</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeshima E., Liang X.M., Goda M., Otani H., Mune M. The efficacy of vitamin E against oxidative damage and autoantibody production in systemic lupus erythematosus: A preliminary study. Clin. Rheumatol. 2007;26:401&#x2013;404. doi: 10.1007/s10067-006-0477-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-006-0477-x</ArticleId><ArticleId IdType="pubmed">17143589</ArticleId></ArticleIdList></Reference><Reference><Citation>Varghese B., Haase N., Low P.S. Depletion of Folate-Receptor-Positive Macrophages Leads to Alleviation of Symptoms and Prolonged Survival in Two Murine Models of Systemic Lupus Erythematosus. Mol. Pharm. 2007;4:679&#x2013;685. doi: 10.1021/mp0700615.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/mp0700615</ArticleId><ArticleId IdType="pubmed">17848087</ArticleId></ArticleIdList></Reference><Reference><Citation>Ardoin S., Sandborg C., Schanberg L. Review: Management of dyslipidemia in children and adolescents with systemic lupus erythematosus. Lupus. 2007;16:618&#x2013;626. doi: 10.1177/0961203307079566.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203307079566</ArticleId><ArticleId IdType="pubmed">17711898</ArticleId></ArticleIdList></Reference><Reference><Citation>Bikle D.D. Vitamin D Metabolism, Mechanism of Action, and Clinical Applications. Chem. Biol. 2014;21:319&#x2013;329. doi: 10.1016/j.chembiol.2013.12.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chembiol.2013.12.016</ArticleId><ArticleId IdType="pmc">PMC3968073</ArticleId><ArticleId IdType="pubmed">24529992</ArticleId></ArticleIdList></Reference><Reference><Citation>Dankers W., Colin E.M., van Hamburg J.P., Lubberts E. Vitamin D in Autoimmunity: Molecular Mechanisms and Therapeutic Potential. Front. Immunol. 2017;7:697. doi: 10.3389/fimmu.2016.00697.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2016.00697</ArticleId><ArticleId IdType="pmc">PMC5247472</ArticleId><ArticleId IdType="pubmed">28163705</ArticleId></ArticleIdList></Reference><Reference><Citation>Illescas-Montes R., Melguizo-Rodr&#xed;guez L., Ruiz C., Costela-Ruiz V.J. Vitamin D and autoimmune diseases. Life Sci. 2019;233:116744. doi: 10.1016/j.lfs.2019.116744.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2019.116744</ArticleId><ArticleId IdType="pubmed">31401314</ArticleId></ArticleIdList></Reference><Reference><Citation>Penna G., Adorini L. 1&#x3b1;,25-Dihydroxyvitamin D 3 Inhibits Differentiation, Maturation, Activation, and Survival of Dendritic Cells Leading to Impaired Alloreactive T Cell Activation. J Immunol. 2000;164:2405&#x2013;2411. doi: 10.4049/jimmunol.164.5.2405.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.164.5.2405</ArticleId><ArticleId IdType="pubmed">10679076</ArticleId></ArticleIdList></Reference><Reference><Citation>Smolders J., Peelen E., Thewissen M., Cohen Tervaert J.W., Menheere P., Hupperts R., Damoiseaux J. Safety and T Cell Modulating Effects of High Dose Vitamin D3 Supplementation in Multiple Sclerosis. PLoS ONE. 2010;5:e15235. doi: 10.1371/journal.pone.0015235.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0015235</ArticleId><ArticleId IdType="pmc">PMC3001453</ArticleId><ArticleId IdType="pubmed">21179201</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavi Arab F., Rastin M., Faraji F., Zamani Taghizadeh Rabe S., Tabasi N., Khazaee M., Haghmorad D., Mahmoudi M. Assessment of 1,25-dihydroxyvitamin D3 effects on Treg cells in a mouse model of systemic lupus erythematosus. Immunopharmacol. Immunotoxicol. 2015;37:12&#x2013;18. doi: 10.3109/08923973.2014.968255.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/08923973.2014.968255</ArticleId><ArticleId IdType="pubmed">25318538</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemire J.M., Ince A., Takashima M. 1,25-Dihydroxyvitamin D 3 Attenuates of Expression of Experimental Murine Lupus of MRL/1 Mice. Autoimmunity. 1992;12:143&#x2013;148. doi: 10.3109/08916939209150321.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/08916939209150321</ArticleId><ArticleId IdType="pubmed">1617111</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds J.A., Haque S., Williamson K., Ray D.W., Alexander M.Y., Bruce I.N. Vitamin D improves endothelial dysfunction and restores myeloid angiogenic cell function via reduced CXCL-10 expression in systemic lupus erythematosus. Sci. Rep. 2016;6:22341. doi: 10.1038/srep22341.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep22341</ArticleId><ArticleId IdType="pmc">PMC4772382</ArticleId><ArticleId IdType="pubmed">26930567</ArticleId></ArticleIdList></Reference><Reference><Citation>Manson J.E., Bassuk S.S., Lee I.M., Cook N.R., Albert M.A., Gordon D., Zaharris E., MacFadyen J.G., Danielson E., Lin J., et al. The VITamin D and OmegA-3 TriaL (VITAL): Rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp. Clin. Trials. 2012;33:159&#x2013;171. doi: 10.1016/j.cct.2011.09.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cct.2011.09.009</ArticleId><ArticleId IdType="pmc">PMC3253961</ArticleId><ArticleId IdType="pubmed">21986389</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiao H., Acar G., Robinson G.A., Ciurtin C., Jury E.C., Kalea A.Z. Diet and Systemic Lupus Erythematosus (SLE): From Supplementation to Intervention. IJERPH. 2022;19:11895. doi: 10.3390/ijerph191911895.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph191911895</ArticleId><ArticleId IdType="pmc">PMC9565311</ArticleId><ArticleId IdType="pubmed">36231195</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert C.M. Effect of Folic Acid and B-Vitamins on Risk of Cardiovascular Events and Total Mortality among Women at High Risk for Cardiovascular Disease: A Randomized Trial. JAMA. 2009;299:2027&#x2013;2036. doi: 10.1001/jama.299.17.2027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.299.17.2027</ArticleId><ArticleId IdType="pmc">PMC2684623</ArticleId><ArticleId IdType="pubmed">18460663</ArticleId></ArticleIdList></Reference><Reference><Citation>Lozovoy M.A.B., Sim&#xe3;o A.N.C., Morimoto H.K., Scavuzzi B.M., Iriyoda T.V.M., Reiche E.M.V., Cecchini R., Dichi I. Fish oil n-3 fatty acids increase adiponectin and decrease leptin levels in patients with systemic lupus erythematosus. Marine Drugs. 2015;13:1071&#x2013;1083. doi: 10.3390/md13021071.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/md13021071</ArticleId><ArticleId IdType="pmc">PMC4344620</ArticleId><ArticleId IdType="pubmed">25690094</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright S., O&#x2019;Prey F.M., McHenry M.T., Leahey W.J., Devine A.B., Duffy E.M., Johnston D.G., Finch M.B., Bell A.L., McVeigh G.E. A randomised interventional trial of &#x3c9;-3-polyunsaturated fatty acids on endothelial function and disease activity in systemic lupus erythematosus. Ann. Rheum. Dis. 2008;67:841&#x2013;848. doi: 10.1136/ard.2007.077156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2007.077156</ArticleId><ArticleId IdType="pubmed">17875549</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorczyca D., Szponar B., Pa&#x15b;ciak M., Czajkowska A., Szmyrka M. Serum levels of n-3 and n-6 polyunsaturated fatty acids in patients with systemic lupus erythematosus and their association with disease activity: A pilot study. Scand. J. Rheumatol. 2022;51:230&#x2013;236. doi: 10.1080/03009742.2021.1923183.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03009742.2021.1923183</ArticleId><ArticleId IdType="pubmed">34169789</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam L.S., Li E.K., Leung V.Y.F., Griffith J.F., Benzie I.F.F., Lim P.L., Whitney B., Lee V.W.Y., Lee K.K.C., Thomas G.N., et al. Effects of vitamins C and E on oxidative stress markers and endothelial function in patients with systemic lupus erythematosus: A double blind, placebo controlled pilot study. J. Rheumatol. 2005;32:275&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pubmed">15693087</ArticleId></ArticleIdList></Reference><Reference><Citation>Vianna A.C.A., Mocelin A.J., Matsuo T., Morais-Filho D., Largura A., Delfino V.A., Soares A.E., Matni A.M. Uremic hyperhomocysteinemia: A randomized trial of folate treatment for the prevention of cardiovascular events. Hemodial. Int. 2007;11:210&#x2013;216. doi: 10.1111/j.1542-4758.2007.00171.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1542-4758.2007.00171.x</ArticleId><ArticleId IdType="pubmed">17403173</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang P., Yang C., Guo H., Wang J., Lin S., Li H., Yang Y., Ling W. Treatment of coenzyme Q10 for 24 weeks improves lipid and glycemic profile in dyslipidemic individuals. J. Clin. Lipidol. 2018;12:417&#x2013;427.e5. doi: 10.1016/j.jacl.2017.12.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacl.2017.12.006</ArticleId><ArticleId IdType="pubmed">29454678</ArticleId></ArticleIdList></Reference><Reference><Citation>Kie&#xdf;ling G., Schneider J., Jahreis G. Long-term consumption of fermented dairy products over 6 months increases HDL cholesterol. Eur. J. Clin. Nutr. 2002;56:843&#x2013;849. doi: 10.1038/sj.ejcn.1601399.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ejcn.1601399</ArticleId><ArticleId IdType="pubmed">12209372</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulati S., Misra A., Pandey R.M. Effects of 3 g of soluble fiber from oats on lipid levels of Asian Indians&#x2014;A randomized controlled, parallel arm study. Lipids Health Dis. 2017;16:71. doi: 10.1186/s12944-017-0460-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12944-017-0460-3</ArticleId><ArticleId IdType="pmc">PMC5381086</ArticleId><ArticleId IdType="pubmed">28376899</ArticleId></ArticleIdList></Reference><Reference><Citation>Mottaghi A., Ebrahimof S., Angoorani P., Saboor-Yaraghi A.A. Vitamin A Supplementation Reduces IL-17 and RORc Gene Expression in Atherosclerotic Patients. Scand. J. Immunol. 2014;80:151&#x2013;157. doi: 10.1111/sji.12190.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/sji.12190</ArticleId><ArticleId IdType="pubmed">24845870</ArticleId></ArticleIdList></Reference><Reference><Citation>Rashidi B.H., Mohammad Hosseinzadeh F., Alipoor E., Asghari S., Yekaninejad M.S., Hosseinzadeh-Attar M.J. Effects of Selenium Supplementation on Asymmetric Dimethylarginine and Cardiometabolic Risk Factors in Patients with Polycystic Ovary Syndrome. Biol. Trace Elem. Res. 2020;196:430&#x2013;437. doi: 10.1007/s12011-019-01954-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12011-019-01954-6</ArticleId><ArticleId IdType="pubmed">31667685</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuttall S.L. Cardiovascular risk in systemic lupus erythematosus--evidence of increased oxidative stress and dyslipidaemia. Rheumatology. 2003;42:758&#x2013;762. doi: 10.1093/rheumatology/keg212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keg212</ArticleId><ArticleId IdType="pubmed">12730535</ArticleId></ArticleIdList></Reference><Reference><Citation>W&#xf3;jcik P., G&#x119;gotek A., &#x17d;arkovi&#x107; N., Skrzydlewska E. Oxidative Stress and Lipid Mediators Modulate Immune Cell Functions in Autoimmune Diseases. IJMS. 2021;22:723. doi: 10.3390/ijms22020723.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22020723</ArticleId><ArticleId IdType="pmc">PMC7828321</ArticleId><ArticleId IdType="pubmed">33450863</ArticleId></ArticleIdList></Reference><Reference><Citation>Hlais S., Reslan D.R.A., Sarieddine H.K., Nasreddine L., Taan G., Azar S., Obeid O.A. Effect of Lysine, Vitamin B6, and Carnitine Supplementation on the Lipid Profile of Male Patients With Hypertriglyceridemia: A 12-Week, Open-Label, Randomized, Placebo-Controlled Trial. Clin. Ther. 2012;34:1674&#x2013;1682. doi: 10.1016/j.clinthera.2012.06.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2012.06.019</ArticleId><ArticleId IdType="pubmed">22818869</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>